The effects of epigallocatechin-3-gallate on blood lipids in humans with moderately elevated cholesterol – a pilot study

Nenad NAUMOVSKI, Barbara Blades, Paul D. Roach

Research output: Contribution to conference (non-published works)Abstract

Abstract

Background A high consumption of green tea has been linked with lower blood cholesterol, an effect primarily ascribed to its most abundant polyphenolic compound epigallocatechin gallate (EGCG). However, studies investigating the effects of EGCG on blood lipids in humans are scarce. Objective The aim of this pilot study was to determine the effect of EGCG supplementation on blood lipids in moderately hypercholesterolaemic humans. Design Ten participants (6 males and 4 females) with moderately elevated cholesterol between 5.5 and 7.5 mmol/l were recruited. A double blind, randomised, placebo-controlled, parallel design was used to study the effects of 1g EGCG/day (treatment) or 1g/day gelatine (control), given in 4 X 250 mg capsules, for 4 weeks. Fasting blood samples were collected at baseline and at the end of the study and total cholesterol, HDL cholesterol and triglycerides were measured in plasma using commercially available kits. The LDL cholesterol was calculated using the Friedewald equation. Participants were asked to record their dietary intake on three consecutive days at baseline and at the end of the study and the macronutrient profile of their diets was analysed using FoodWorks 2009 Professional (v6 Xyris Software). Outcomes The LDL cholesterol significantly increased during the 4-week treatment period in the control group (+13.3%, P=0.016) but there was no significant change in the EGCG group (+4.8%, P=0.365). The same trend was seen for total cholesterol in the control group (+8.6%, P=0.060) but it did not reach statistical significance. In the EGCG group, there was no change in total cholesterol (+0.77%, P=0.768). There were no significant differences in triglycerides in either group during the treatment period (P>0.05). There were also no changes in the dietary intake of macronutrients in either group during the 4 weeks of treatment (P>0.05). Conclusion The results of this pilot study indicate that EGCG suppressed the rise in LDL cholesterol which was seen in the control group. Therefore, further studies investigating EGCG as an hypocholesterolaemic agent are warranted in higher numbers of subjects. Source of funding N. Naumovski was the recipient of an APA Scholarship from the University of Newcastle.
Original languageEnglish
Publication statusPublished - 2010
Externally publishedYes
EventAnnual Scientific Meeting of the Nutrition-Society-of-Australia -
Duration: 1 Jan 2011 → …

Conference

ConferenceAnnual Scientific Meeting of the Nutrition-Society-of-Australia
Period1/01/11 → …

Fingerprint

Hypercholesterolemia
Lipids
Cholesterol
LDL Cholesterol
Control Groups
Triglycerides
Diet Records
epigallocatechin gallate
Tea
Therapeutics
HDL Cholesterol
Capsules
Fasting
Software
Placebos
Diet

Cite this

NAUMOVSKI, N., Blades, B., & Roach, P. D. (2010). The effects of epigallocatechin-3-gallate on blood lipids in humans with moderately elevated cholesterol – a pilot study. Abstract from Annual Scientific Meeting of the Nutrition-Society-of-Australia, .
NAUMOVSKI, Nenad ; Blades, Barbara ; Roach, Paul D. / The effects of epigallocatechin-3-gallate on blood lipids in humans with moderately elevated cholesterol – a pilot study. Abstract from Annual Scientific Meeting of the Nutrition-Society-of-Australia, .
@conference{a3c72edeabaa47feaa21325db2cbd29b,
title = "The effects of epigallocatechin-3-gallate on blood lipids in humans with moderately elevated cholesterol – a pilot study",
abstract = "Background A high consumption of green tea has been linked with lower blood cholesterol, an effect primarily ascribed to its most abundant polyphenolic compound epigallocatechin gallate (EGCG). However, studies investigating the effects of EGCG on blood lipids in humans are scarce. Objective The aim of this pilot study was to determine the effect of EGCG supplementation on blood lipids in moderately hypercholesterolaemic humans. Design Ten participants (6 males and 4 females) with moderately elevated cholesterol between 5.5 and 7.5 mmol/l were recruited. A double blind, randomised, placebo-controlled, parallel design was used to study the effects of 1g EGCG/day (treatment) or 1g/day gelatine (control), given in 4 X 250 mg capsules, for 4 weeks. Fasting blood samples were collected at baseline and at the end of the study and total cholesterol, HDL cholesterol and triglycerides were measured in plasma using commercially available kits. The LDL cholesterol was calculated using the Friedewald equation. Participants were asked to record their dietary intake on three consecutive days at baseline and at the end of the study and the macronutrient profile of their diets was analysed using FoodWorks 2009 Professional (v6 Xyris Software). Outcomes The LDL cholesterol significantly increased during the 4-week treatment period in the control group (+13.3{\%}, P=0.016) but there was no significant change in the EGCG group (+4.8{\%}, P=0.365). The same trend was seen for total cholesterol in the control group (+8.6{\%}, P=0.060) but it did not reach statistical significance. In the EGCG group, there was no change in total cholesterol (+0.77{\%}, P=0.768). There were no significant differences in triglycerides in either group during the treatment period (P>0.05). There were also no changes in the dietary intake of macronutrients in either group during the 4 weeks of treatment (P>0.05). Conclusion The results of this pilot study indicate that EGCG suppressed the rise in LDL cholesterol which was seen in the control group. Therefore, further studies investigating EGCG as an hypocholesterolaemic agent are warranted in higher numbers of subjects. Source of funding N. Naumovski was the recipient of an APA Scholarship from the University of Newcastle.",
author = "Nenad NAUMOVSKI and Barbara Blades and Roach, {Paul D.}",
year = "2010",
language = "English",
note = "Annual Scientific Meeting of the Nutrition-Society-of-Australia ; Conference date: 01-01-2011",

}

NAUMOVSKI, N, Blades, B & Roach, PD 2010, 'The effects of epigallocatechin-3-gallate on blood lipids in humans with moderately elevated cholesterol – a pilot study' Annual Scientific Meeting of the Nutrition-Society-of-Australia, 1/01/11, .

The effects of epigallocatechin-3-gallate on blood lipids in humans with moderately elevated cholesterol – a pilot study. / NAUMOVSKI, Nenad; Blades, Barbara; Roach, Paul D.

2010. Abstract from Annual Scientific Meeting of the Nutrition-Society-of-Australia, .

Research output: Contribution to conference (non-published works)Abstract

TY - CONF

T1 - The effects of epigallocatechin-3-gallate on blood lipids in humans with moderately elevated cholesterol – a pilot study

AU - NAUMOVSKI, Nenad

AU - Blades, Barbara

AU - Roach, Paul D.

PY - 2010

Y1 - 2010

N2 - Background A high consumption of green tea has been linked with lower blood cholesterol, an effect primarily ascribed to its most abundant polyphenolic compound epigallocatechin gallate (EGCG). However, studies investigating the effects of EGCG on blood lipids in humans are scarce. Objective The aim of this pilot study was to determine the effect of EGCG supplementation on blood lipids in moderately hypercholesterolaemic humans. Design Ten participants (6 males and 4 females) with moderately elevated cholesterol between 5.5 and 7.5 mmol/l were recruited. A double blind, randomised, placebo-controlled, parallel design was used to study the effects of 1g EGCG/day (treatment) or 1g/day gelatine (control), given in 4 X 250 mg capsules, for 4 weeks. Fasting blood samples were collected at baseline and at the end of the study and total cholesterol, HDL cholesterol and triglycerides were measured in plasma using commercially available kits. The LDL cholesterol was calculated using the Friedewald equation. Participants were asked to record their dietary intake on three consecutive days at baseline and at the end of the study and the macronutrient profile of their diets was analysed using FoodWorks 2009 Professional (v6 Xyris Software). Outcomes The LDL cholesterol significantly increased during the 4-week treatment period in the control group (+13.3%, P=0.016) but there was no significant change in the EGCG group (+4.8%, P=0.365). The same trend was seen for total cholesterol in the control group (+8.6%, P=0.060) but it did not reach statistical significance. In the EGCG group, there was no change in total cholesterol (+0.77%, P=0.768). There were no significant differences in triglycerides in either group during the treatment period (P>0.05). There were also no changes in the dietary intake of macronutrients in either group during the 4 weeks of treatment (P>0.05). Conclusion The results of this pilot study indicate that EGCG suppressed the rise in LDL cholesterol which was seen in the control group. Therefore, further studies investigating EGCG as an hypocholesterolaemic agent are warranted in higher numbers of subjects. Source of funding N. Naumovski was the recipient of an APA Scholarship from the University of Newcastle.

AB - Background A high consumption of green tea has been linked with lower blood cholesterol, an effect primarily ascribed to its most abundant polyphenolic compound epigallocatechin gallate (EGCG). However, studies investigating the effects of EGCG on blood lipids in humans are scarce. Objective The aim of this pilot study was to determine the effect of EGCG supplementation on blood lipids in moderately hypercholesterolaemic humans. Design Ten participants (6 males and 4 females) with moderately elevated cholesterol between 5.5 and 7.5 mmol/l were recruited. A double blind, randomised, placebo-controlled, parallel design was used to study the effects of 1g EGCG/day (treatment) or 1g/day gelatine (control), given in 4 X 250 mg capsules, for 4 weeks. Fasting blood samples were collected at baseline and at the end of the study and total cholesterol, HDL cholesterol and triglycerides were measured in plasma using commercially available kits. The LDL cholesterol was calculated using the Friedewald equation. Participants were asked to record their dietary intake on three consecutive days at baseline and at the end of the study and the macronutrient profile of their diets was analysed using FoodWorks 2009 Professional (v6 Xyris Software). Outcomes The LDL cholesterol significantly increased during the 4-week treatment period in the control group (+13.3%, P=0.016) but there was no significant change in the EGCG group (+4.8%, P=0.365). The same trend was seen for total cholesterol in the control group (+8.6%, P=0.060) but it did not reach statistical significance. In the EGCG group, there was no change in total cholesterol (+0.77%, P=0.768). There were no significant differences in triglycerides in either group during the treatment period (P>0.05). There were also no changes in the dietary intake of macronutrients in either group during the 4 weeks of treatment (P>0.05). Conclusion The results of this pilot study indicate that EGCG suppressed the rise in LDL cholesterol which was seen in the control group. Therefore, further studies investigating EGCG as an hypocholesterolaemic agent are warranted in higher numbers of subjects. Source of funding N. Naumovski was the recipient of an APA Scholarship from the University of Newcastle.

UR - https://www.researchgate.net/publication/276156157_The_effects_of_epigallocatechin-3-gallate_on_blood_lipids_in_humans_with_moderately_elevated_cholesterol_-_a_pilot_study

M3 - Abstract

ER -

NAUMOVSKI N, Blades B, Roach PD. The effects of epigallocatechin-3-gallate on blood lipids in humans with moderately elevated cholesterol – a pilot study. 2010. Abstract from Annual Scientific Meeting of the Nutrition-Society-of-Australia, .